108 related articles for article (PubMed ID: 9210715)
1. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
[TBL] [Abstract][Full Text] [Related]
2. [Exploration and validation of optimal cut-off values for tPSA and fPSA/tPSA screening of prostate cancer at different ages].
Liu XM; Duan HY; Zhang DQ; Chen C; Ji YT; Zhang YM; Feng ZW; Liu Y; Li JJ; Zhang Y; Li CY; Zhang YC; Yang L; Lyu ZY; Song FF; Song FJ; Huang YB
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):354-364. PubMed ID: 38644271
[No Abstract] [Full Text] [Related]
3. The predictability of T3 disease in staging MRI following prostate biopsy decreases in patients with high initial PSA and Gleason score.
Hwii Ko Y; Jae Sung D; Gu Kang S; Ho Kang S; Gu Lee J; Jong Kim J; Cheon J
Asian J Androl; 2011 May; 13(3):487-93. PubMed ID: 21383671
[TBL] [Abstract][Full Text] [Related]
4. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.
Sokoll LJ; Sanda MG; Feng Z; Kagan J; Mizrahi IA; Broyles DL; Partin AW; Srivastava S; Thompson IM; Wei JT; Zhang Z; Chan DW
Cancer Epidemiol Biomarkers Prev; 2010 May; 19(5):1193-200. PubMed ID: 20447916
[TBL] [Abstract][Full Text] [Related]
5. PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience.
Merola R; Tomao L; Antenucci A; Sperduti I; Sentinelli S; Masi S; Mandoj C; Orlandi G; Papalia R; Guaglianone S; Costantini M; Cusumano G; Cigliana G; Ascenzi P; Gallucci M; Conti L
J Exp Clin Cancer Res; 2015 Feb; 34(1):15. PubMed ID: 25651917
[TBL] [Abstract][Full Text] [Related]
6. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes.
Carvalhal GF; Daudi SN; Kan D; Mondo D; Roehl KA; Loeb S; Catalona WJ
Urology; 2010 Nov; 76(5):1072-6. PubMed ID: 20846711
[TBL] [Abstract][Full Text] [Related]
7. Does prostate-specific antigen (PSA) mass or free PSA mass improve the accuracy of predicting total prostate volume in relation to obesity in men with biopsy-proven benign prostatic hyperplasia?
Jung JW; Yu YD; Lee YJ; Kim JJ; Lee HM; Oh JJ; Lee S; Lee SW; Lee SE; Jeong SJ
Asian J Androl; 2018 Sep; 21(1):86-91. PubMed ID: 30178776
[TBL] [Abstract][Full Text] [Related]
8. Interassay Variability and Clinical Implications of Five Different Prostate-specific Antigen Assays.
Kaufmann B; Pellegrino P; Zuluaga L; Ben-David R; Müntener M; Keller EX; Spanaus K; von Eckardstein A; Gorin MA; Poyet C
Eur Urol Open Sci; 2024 May; 63():4-12. PubMed ID: 38558765
[TBL] [Abstract][Full Text] [Related]
9. Predicting Positive Repeat Prostate Biopsy Outcomes: Comparison of Machine Learning Approaches to Identify Key Parameters and Optimal Algorithms.
Zhang X; Feng C; Bai X; Peng X; Guo Q; Chen L; Xue J
Arch Esp Urol; 2023 Sep; 76(7):494-503. PubMed ID: 37867334
[TBL] [Abstract][Full Text] [Related]
10. Lectin-nanoparticle concept for free PSA glycovariant providing superior cancer specificity.
Kekki H; Montoya Perez I; Taimen P; Boström PJ; Gidwani K; Pettersson K
Clin Chim Acta; 2024 Jun; 559():119689. PubMed ID: 38677453
[TBL] [Abstract][Full Text] [Related]
11. The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy.
Lokeshwar SD; Ali A; Weiss TR; Reynolds J; Shuch BM; Ferencz T; Kyriakides TC; Mehal WZ; Brito J; Renzulli J; Leapman MS
BMC Urol; 2024 May; 24(1):102. PubMed ID: 38702664
[TBL] [Abstract][Full Text] [Related]
12. Mechanism underlying the negative effect of prostate volume on the outcome of extensive transperineal ultrasound-guided template prostate biopsy.
Demura T; Takada T; Shimoda N; Hioka T; Iwaguchi Y; Ichihara S; Gotoda H
Cancer Med; 2018 Feb; 7(2):336-343. PubMed ID: 29341453
[TBL] [Abstract][Full Text] [Related]
13. Precise prostate cancer diagnosis using fluorescent nanoprobes for detecting PSA and PSMA in serum.
Ouyang M; Jia M; Chang Z; Wang Y; Wang K; Gao X; Tang B
Chem Commun (Camb); 2024 May; 60(39):5181-5184. PubMed ID: 38647078
[TBL] [Abstract][Full Text] [Related]
14. Serum methionine metabolites are risk factors for metastatic prostate cancer progression.
Stabler S; Koyama T; Zhao Z; Martinez-Ferrer M; Allen RH; Luka Z; Loukachevitch LV; Clark PE; Wagner C; Bhowmick NA
PLoS One; 2011; 6(8):e22486. PubMed ID: 21853037
[TBL] [Abstract][Full Text] [Related]
15. Glycoprofiling of proteins as prostate cancer biomarkers: A multinational population study.
Pinkeova A; Tomikova A; Bertokova A; Fabinyova E; Bartova R; Jane E; Hroncekova S; Sievert KD; Sokol R; Jirasko M; Kucera R; Eder IE; Horninger W; Klocker H; Ďubjaková P; Fillo J; Bertok T; Tkac J
PLoS One; 2024; 19(3):e0300430. PubMed ID: 38498504
[TBL] [Abstract][Full Text] [Related]
16. Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?
Loeb S; Roehl KA; Helfand BT; Kan D; Catalona WJ
J Urol; 2010 Jan; 183(1):112-6. PubMed ID: 19913814
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of serum tumor abnormal protein in prostate cancer patients.
Fu L; Zhang C; Wang Z; Tao W; Zhu J; Zhou Y; Sun C; Xue B; Yu M; Xu L; Zang Y
BMC Cancer; 2024 May; 24(1):665. PubMed ID: 38822321
[TBL] [Abstract][Full Text] [Related]
18. Elevation of Serum Prostate-Specific Antigen Levels in Males With Pulmonary Embolism.
Peng YF; Ma LY; Luo M
Clin Appl Thromb Hemost; 2024; 30():10760296241250002. PubMed ID: 38779806
[TBL] [Abstract][Full Text] [Related]
19. Limited prognostic role of routine serum markers (AP, CEA, LDH and NSE) in oligorecurrent prostate cancer patients undergoing PSMA-radioguided surgery.
Mehring G; Steinbach C; Pose R; Knipper S; Koehler D; Werner S; Riethdorf S; von Amsberg G; Ambrosini F; Maurer T
World J Urol; 2024 Apr; 42(1):256. PubMed ID: 38656636
[TBL] [Abstract][Full Text] [Related]
20. Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers.
Li QK; Chen L; Ao MH; Chiu JH; Zhang Z; Zhang H; Chan DW
Theranostics; 2015; 5(3):267-76. PubMed ID: 25553114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
